Advanced Micro Devices, Inc. (AMD)
AMD Stock Continues To Be A No Brainer (Technical Analysis)
AMD remains a buy as technicals show a bullish outlook, with strong support levels and an intact uptrend, despite some caution from Fibonacci Fan Lines. Q1 earnings were impressive, with 36% YoY revenue growth and 57% YoY growth in the Data Center segment, highlighting AI business strength. Q2 guidance projects continued above-average revenue growth, and gross margins would be strong if not for China's export controls.
AMD acqui-hires the employees behind Untether AI
AMD is continuing its acquisition spree.
Is Trending Stock Advanced Micro Devices, Inc. (AMD) a Buy Now?
Zacks.com users have recently been watching Advanced Micro (AMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AMD: Trend Reversal In Sight
I upgraded my rating to a strong buy. Call options are expensive (high IV), so I haven't opened a long position in this stock. Q1 results show a continuation in growth, driven by the data center and (finally) the client segments. The upcoming launch of the MI350 series is a nice catalyst ahead. The partnership with Oracle and Humain is a clear indication that AI infrastructure companies are betting on AMD's GPUs and (emphasis) CPUs.
AMD vs. Semtech: Which Semiconductor Stock Is the Better Buy Now?
Advanced Micro Devices and SMTC are well-known players in the semiconductor market. Let's find out which one is a better investment option right now.
Why Is Advanced Micro (AMD) Up 18.2% Since Last Earnings Report?
Advanced Micro (AMD) reported earnings 30 days ago. What's next for the stock?
Advanced Micro Devices (AMD) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Advanced Micro Devices (AMD) closed at $118.58, marking a +1.08% move from the previous day.
AMD takes aim at Nvidia's AI hardware dominance with Brium acquisition
AMD's latest acquisition could help reduce Nvidia's market dominance when it comes to AI hardware.
Advanced Micro Devices, Inc. (AMD) Bank of America Global Technology Conference - (Transcript)
Advanced Micro Devices, Inc. (NASDAQ:AMD ) Bank of America Global Technology Conference Call June 3, 2025 11:40 AM ET Company Participants Jean X. Hu - Executive VP, CFO & Treasurer Matthew D.
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
LYTENAVAâ„¢ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year 1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVAâ„¢ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD).
AMD: Take Full Advantage Of The Solid Nvidia Earnings
Nvidia Corporation's strong outlook and favorable tariff ruling has boosted semiconductor sentiment, mitigating China headwinds and supporting sector resilience. Advanced Micro Devices, Inc.'s Q1 results and ongoing data center momentum reinforce confidence in its core business, despite cyclical and competitive challenges. AI growth remains AMD's key catalyst; upcoming investor day is crucial for management to clarify long-term AI revenue outlook and drive re-rating.
Nvidia is surging; Here are 3 stocks to follow
Nvidia (NASDAQ: NVDA ) has just reported no less than $44.06 billion in revenue for the previous quarter and is up 6% premarket.
